Please assess the completion status of the following clinical trial:

Trial Title: Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-50 years; military, civilian, male and female.~2. Able to provide consent to participate and having signed an Informed Consent Form.~3. Able and willing to comply with all study procedures.~4. Women of child-bearing potential agree to remain sexually abstinent, use medically effective contraception (oral contraception, barrier methods, spermicide, etc.) or have a partner who is sterile from enrollment to 3 months following the last injection, or have a partner who is unable to induce pregnancy.~5. Sexually active men who are considered sexually fertile must agree to use either a barrier method of contraception during the study, and agree to continue the use for at least 3 months following the last injection, or have a partner who is permanently sterile or unable to become pregnant;~6. Normal screening ECG or screening ECG with no clinically significant findings;~7. Screening labs must be within normal limits or have only Grade 0-1 findings;~8. No history of clinically significant immunosuppressive or autoimmune disease.~9. Not currently or within the previous 4 weeks taking immunosuppressive agents (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or corticosteroids at a dose less than 20 mg/day).~10. Willing to allow storage and future use of samples for MERS CoV related research~Exclusion Criteria:~1. Administration of an investigational compound either currently or within 30 days of first dose;~2. Previous receipt of an investigational product for the treatment or prevention of MERS CoV except if participant is verified to have received placebo;~3. Previous infection with MERS CoV as assessed by self report and solicited exposure history;~4. Administration of any vaccine within 4 weeks of first dose;~5. A BMI greater than or equal to 35;~6. Administration of any monoclonal or polyclonal antibody product within 4 weeks of the first dose;~7. Administration of any blood product within 3 months of first dose;~8. Pregnancy or breast feeding or have plans to become pregnant during the course of the study;~9. History of positive serologic test for HIV, hepatitis B surface antigen (HBsAg); or any potentially communicable infectious disease as determined by the Principal Investigator or Medical Monitor;~10. Positive serologic test for hepatitis C (exception: successful treatment with confirmation of sustained virologic response);~11. Baseline evidence of kidney disease as measured by creatinine greater than 1.5 (CKD Stage II or greater);~12. Baseline screening lab(s) with Grade 2 or higher abnormality;~13. Chronic liver disease or cirrhosis;~14. Immunosuppressive illness including hematologic malignancy, history of solid organ or bone marrow transplantation;~15. Current or anticipated concomitant immunosuppressive therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or corticosteroids at a dose less than 20 mg/day);~16. Current or anticipated treatment with TNF-α inhibitors such as infliximab, adalimumab, etanercept;~17. Prior major surgery or any radiation therapy within 4 weeks of group assignment;~18. Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome;~19. Presence of a cardiac pacemaker or automatic implantable cardioverter defibrillator (AICD);~20. Metal implants within 20 cm of the planned site(s) of injection;~21. Presence of keloid scar formation or hypertrophic scar as a clinically significant medical condition at the planned site(s) of injection.~22. Prisoner or participants who are compulsorily detained (involuntary incarceration) for treatment of either a physical or psychiatric illness;~23. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements or assessment of immunologic endpoints; or~24. Tattoos covering the injection site area h~25. Any illness or condition that in the opinion of the investigator may affect the safety of the participant or the evaluation of any study endpoint.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- GLS-5300 (Type: EXPERIMENTAL): GLS-5300 at 0.67 mg DNA/dose
- GLS-5300 at 2 mg DNA/dose (Type: EXPERIMENTAL): GLS-5300 at 2 mg DNA/dose
- GLS-5300 at 6 mg DNA/dose (Type: EXPERIMENTAL): GLS-5300 at 6 mg DNA/dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete